Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
Business Wire•03/11/2026•06:30 ET
0
Key Highlights
- ➤Final NDA submission due within two weeks; rolling review is already underway
- ➤Cash and equivalents $444.0 million, funding operations and capital expenditures into 2028
- ➤Launch readiness on track for expected H1 2027 launch, subject to FDA approval
- ➤R&D expenses fell to $23.5 million in Q3 2026 from $27.3 million
- ➤SG&A expenses rose to $33.0 million amid commercial launch preparations
Expert Statements
Kabir Nath, Chief Executive Officer of Compass Pathways
“Compass is leading one of the most important advances in mental health care in decades. Millions of people living with TRD are waiting for new treatments that can deliver meaningful and lasting benefit, and we believe COMP360 has the potential to change the paradigm”
Kabir Nath, Chief Executive Officer of Compass Pathways
“With the imminent completion of our NDA submission and the potential for a quick approval, we are executing with urgency and discipline to launch this much needed treatment in the first half of 2027. At the same time, we continue to advance our PTSD program, extending the potential impact of COMP360 to additional patient populations with significant unmet need. With a robust clinical package, a clear path forward, and a launch-ready organization, Compass is well positioned to deliver a successful TRD launch.”
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
* Final NDA submission nearing completion and will be filed in the next two weeks
Get started
Create a free account to read the full story.